急性腎不全の世界市場：2024年～2031年

概要

世界の急性腎不全市場は、2023年に530万米ドルに達し、2031年には1,102万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは9.0%で成長する見込みです。

急性腎障害（AKI）としても知られる急性腎不全（ARF）は、重度の脱水、感染症、特定の薬剤、糖尿病や高血圧などの基礎疾患などの要因によって引き起こされる腎機能の急激な低下です。その結果、腎臓が老廃物や過剰な水分をろ過できなくなり、体内に有毒物質が蓄積します。ARFは、尿量の減少、体液貯留、電解質の不均衡を特徴とし、生命を脅かす合併症を引き起こす可能性があります。ARFを管理し、慢性腎臓病への進行を防ぐには、迅速な診断と治療が極めて重要です。

市場力学：

促進要因と抑制要因

腎臓病有病率の上昇

急性腎不全（ARF）の有病率の増加は、慢性疾患、高齢化、診断能力の向上などの要因によって、治療市場に影響を与えています。このため、効果的な治療オプションに対する需要が急増しています。

例えば、NCBIに掲載された論文によると、急性腎不全は入院患者によく見られます。米国では、全入院患者の1％が入院時にAKIを発症しています。入院中の急性腎障害の発生率はおおよそ2％から5％で、集中治療室に入院した患者の最大67％に発生します。このように、AKIは入院期間の延長や患者の罹患率を高める重要な要因となっています。

薬剤に伴う副作用

急性腎不全の治療には、利尿薬、血管圧迫薬、赤血球造血刺激因子製剤（ESA）、リン酸結合剤、抗生物質など、さまざまな薬剤が用いられることが多いです。これらの薬剤は、脱水、電解質不均衡、低血圧、不整脈、組織虚血、重症高血圧、血栓塞栓イベント、高血圧、胃腸障害、抗生物質耐性などの副作用を引き起こす可能性があります。

腎機能障害を悪化させたり、さらなる健康障害を引き起こしたりしないよう、これらの副作用を注意深く管理することが極めて重要です。適切な治療と回復を確実にするためには、これらの薬剤を注意深く監視することが不可欠です。

市場セグメンテーション

世界の急性腎不全市場は、疾患タイプ、薬剤タイプ、投与経路、流通チャネル、地域によって区分されます。

薬剤タイプの利尿薬は急性腎不全市場の約41.1%を占める

薬剤タイプ別では、利尿薬が約41.1%を占めました。利尿薬は急性腎不全において、体液過剰と電解質不均衡を管理するために不可欠です。利尿薬は尿量を増加させ、体液量を減少させ、肺水腫や高血圧などの合併症を予防します。また、高カリウム血症のような電解質異常も管理します。しかし、利尿薬の使用は、脱水や電解質不均衡のような潜在的な副作用を避けるために監視されなければならないです。

例えば、2023年12月、100万人以上の成人を対象としたヴァンダービルト大学メディカルセンターの新しい遺伝子関連研究では、腎結石予防のためのサイアザイド系利尿薬の使用が支持されました。腎臓結石は世界人口の10％近くが罹患しています。30年以上にわたって、高血圧の治療薬として一般的なサイアザイド系利尿薬は、尿中カルシウムの排泄を減少させるため、腎結石予防の標準治療薬となっています。

市場地域別シェア

北米は予測期間を通じて市場シェア全体の約38.4%を占めると予測される

北米は、新製品の上市、FDAの承認、急性腎不全の増加などの要因により、予測期間を通じて市場全体の約38.4%を占めると予測されます。

例えば、2023年1月、米国食品医薬品局（FDA）は、慢性腎臓病（CKD）の成人における腎臓病の進行および心血管死亡のリスクを低減する可能性のある治療薬として研究されているジャーディアンス（エンパグリフロジン）錠剤の追加新薬承認申請（sNDA）を受理しました。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 腎臓病有病率の上昇
    • 治療法の進歩
  • 抑制要因
    • 薬剤に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 特許分析
• PESTLE分析
• SWOT分析
• DMIオピニオン

第6章 疾患タイプ別

• 腎前性急性腎不全
• 腎性急性腎不全
• 腎後性急性腎不全

第7章 薬剤タイプ別

• 利尿薬
• 血管圧迫薬
• 赤血球造血刺激因子製剤（ESAs）
• リン酸結合剤
• カルシウムおよびビタミンDサプリメント
• 抗生物質
• その他

第8章 投与経路別

• 経口
• 静脈注射

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Novartis
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Fresenius Medical Care
• Amgen
• Roche
• Baxter International Inc
• Zypharma
• Nature Made
• Pfizer
• GSK
• Eli Lilly（*LIST NOT EXHAUSTIVE）

第13章 付録

Overview

The Global Acute Renal Failure Market reached US$ 5.30 million in 2023 and is expected to reach US$ 11.02 million by 2031, growing at a CAGR of 9.0% during the forecast period 2024-2031.

Acute renal failure (ARF), also known as acute kidney injury (AKI), is a sudden decline in kidney function caused by factors like severe dehydration, infections, certain medications, or underlying medical conditions like diabetes or hypertension. It results in the kidneys' inability to filter waste products and excess fluids, leading to the accumulation of toxic substances in the body. ARF is characterized by decreased urine output, fluid retention, electrolyte imbalances, and potentially life-threatening complications. Prompt diagnosis and treatment are crucial for managing ARF and preventing its progression to chronic kidney disease.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of kidney diseases

The increasing prevalence of acute renal failure (ARF) is influencing the treatment market, driven by factors like chronic diseases, aging populations, and improved diagnostic capabilities. This leads to a surge in demand for effective treatment options.

For instance, according to an article published in NCBI, acute renal failure is commonly seen in hospitalized patients. In the United States, 1% of all hospital admissions have AKI on admission. During hospitalization, the approximate incidence rate of acute kidney injury is 2% to 5%, and it occurs in up to 67% of patients admitted to the intensive care unit. AKI is thus an important contributor to more extended hospital stays and patient morbidity.

Side effects associated with the drugs

Acute renal failure treatment often involves various drugs, including diuretics, vasopressors, erythropoiesis-stimulating agents (ESAs), phosphate binders, antibiotics, and antibiotics. These drugs can cause side effects like dehydration, electrolyte imbalances, hypotension, arrhythmias, tissue ischemia, severe hypertension, thromboembolic events, hypertension, gastrointestinal issues, and antibiotic resistance.

It is crucial to manage these side effects carefully to avoid exacerbating renal dysfunction or causing additional health problems. It is essential to monitor these medications closely to ensure proper treatment and recovery.

Market Segment Analysis

The global acute renal failure market is segmented based on disease type, drug type, route of administration, distribution channel, and region.

The diuretics from the drug type segment accounted for approximately 41.1% of the acute renal failure market share

The diuretics from the drug type segment accounted for approximately 41.1%. Diuretics are essential in acute renal failure to manage fluid overload and electrolyte imbalances. They increase urine production, reducing fluid volume and preventing complications like pulmonary edema and hypertension. They also manage electrolyte disturbances like hyperkalemia, often associated with the condition. However, the use of diuretics must be monitored to avoid potential side effects like dehydration and electrolyte imbalances, which can further stress the renal system.

For instance, in December 2023, A new Vanderbilt University Medical Center genetic association study of more than 1 million adults supported the use of thiazide diuretics for kidney stone prevention. Kidney stones affect nearly 10% of the global population. For more than three decades, thiazide diuretics, a common medication used for high blood pressure, have been the standard of care for kidney stone prevention because they reduce the excretion of urinary calcium.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, FDA approvals, a rise in cases of acute renal failure, and other factors that help the region to grow during the forecast period.

For instance, in January 2023, the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD).

Market Segmentation

By Disease Type

Prerenal Acute Renal Failure

Renal Acute Renal Failure

Postrenal Acute Renal Failure

By Drug Type

Diuretics

Vasopressors

Erythropoiesis-Stimulating Agents (ESAs)

Phosphate Binders

Calcium and Vitamin D Supplements

Antibiotics

Others

By Route of Administration

Oral

Intravenous

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Novartis, Fresenius Medical Care, Amgen, Roche, Baxter International Inc, Zypharma, Nature Made, Pfizer, GSK, and Eli Lilly among others.

Why Purchase the Report?

To visualize the global acute renal failure market segmentation based on disease type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the acute renal failure market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global acute renal failure market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Drug Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the prevalence of kidney diseases
    • 4.1.1.2. Advancements in treatment options
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with the drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Patent Analysis
• 5.6. PESTLE Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Disease Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.1.2. Market Attractiveness Index, By Disease Type
• 6.2. Prerenal Acute Renal Failure*
  • 6.2.1. Introduction
• 6.3. Renal Acute Renal Failure
• 6.4. Postrenal Acute Renal Failure

7. By Drug Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 7.1.2. Market Attractiveness Index, By Drug Type
• 7.2. Diuretics*
  • 7.2.1. Introduction
• 7.3. Vasopressors
• 7.4. Erythropoiesis-Stimulating Agents (ESAs)
• 7.5. Phosphate Binders
• 7.6. Calcium and Vitamin D Supplements
• 7.7. Antibiotics
• 7.8. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
• 8.2. Market Attractiveness Index, By Route of Administration
• 8.3. Oral*
  • 8.3.1. Introduction
  • 8.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.4. Intravenous

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. The U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. UK
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Novartis*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Fresenius Medical Care
• 12.3. Amgen
• 12.4. Roche
• 12.5. Baxter International Inc
• 12.6. Zypharma
• 12.7. Nature Made
• 12.8. Pfizer
• 12.9. GSK
• 12.10. Eli Lilly (*LIST NOT EXHAUSTIVE)

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us